Banner for leaf pages 2

Infliximab (Remicade)

Also known as Remicade

Infliximab (INN; trade name Remicade) is a monoclonal antibody against tumour necrosis factor alpha (TNF-α) used to treat autoimmune diseases. Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the USA, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere.

Source: Wikipedia

Estimated Total Cost: $2995.22 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed infliximab to treat crohn disease, rheumatoid arthritis, ulcerative colitis, and psoriasis.

What drug interactions are known?

Do not take infliximab if you are taking any of the following:

Critical Interactions

Significant Interactions


Ajax-loader Loading...